No Data
No Data
Aclaris Therapeutics(ACRS.US) 10% Shareholder Buys US$1.78 Million in Common Stock
$Aclaris Therapeutics(ACRS.US)$ 10% Shareholder Leonard Braden Michael purchased 1.61 million shares of common stock on Jun 11, 12, 13, 2024 at an average price of $1.1059 for a total value of $1.78 m
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
PDF Version Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference June 6, 2024 WAYNE, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics,
12 Health Care Stocks Moving In Friday's After-Market Session
GainersSharps Technology (NASDAQ:STSS) shares rose 50.5% to $0.32 during Friday's after-market session. The market value of their outstanding shares is at $5.0 million. Cyclacel Pharmaceuticals (NASDA
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) defied analyst predictions to release its first-quarter results, which were ahead of market expectations. Results clearly exceeded expectations, with a su
Analysts Offer Insights on Healthcare Companies: Tango Therapeutics (TNGX), Aclaris Therapeutics (ACRS) and Immunocore Holdings (IMCR)
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript